Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAKE E TURRENTINE

Allopathic & Osteopathic Physicians Dermatology

NPI
1386934933
CMS profile
1318844
Location
HICKORY, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$55,519.33

95 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Galderma Laboratories, L.P. $27,565.21 26
SUN PHARMACEUTICAL INDUSTRIES INC. $17,734.15 13
ABBVIE INC. $9,607.93 17
PFIZER INC. $240.93 22
E.R. Squibb & Sons, L.L.C. $91.62 4
Amgen Inc. $77.17 4
LEO Pharma Inc. $55.70 3
STRATA Skin Sciences, Inc. $54.91 1
Novartis Pharmaceuticals Corporation $40.64 2
Organon LLC $29.01 2
Krystal Biotech Inc $22.06 1

Page 1 of 2; records 1–50 of 95 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAKE E TURRENTINE

NPI 1386934933 · CMS profile ID 1318844

Allopathic & Osteopathic Physicians / Dermatology

HICKORY, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 95 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1386934933?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAKE E TURRENTINE, NPI 1386934933, CMS profile ID 1318844. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 95 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1386934933?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JAKE E TURRENTINE, NPI 1386934933, CMS profile ID 1318844. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 95 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1386934933?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JAKE E TURRENTINE, NPI 1386934933, CMS profile ID 1318844, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 95 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1386934933?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

95 matching records · $55,519.33 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 95 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 95.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $7.5712/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230847618 CMS
Galderma Laboratories, L.P. $7.4412/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234712881 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $1,760.0012/03/2025 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: NEW
06/30/2026 1251004872 CMS
LEO Pharma Inc. $18.9012/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252041114 CMS
ABBVIE INC. $4,550.0012/01/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1204589566 CMS
Novartis Pharmaceuticals Corporation $21.0212/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200435033 CMS
PFIZER INC. $13.8211/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230951834 CMS
PFIZER INC. $3.8211/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230983336 CMS
Galderma Laboratories, L.P. $23.4911/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234712879 CMS
Galderma Laboratories, L.P. $16.9111/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234712877 CMS
PFIZER INC. $4.4311/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230674612 CMS
ABBVIE INC. $125.0011/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204589563 CMS
Krystal Biotech Inc $22.0611/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1199996732 CMS
E.R. Squibb & Sons, L.L.C. $21.8711/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184538374 CMS
Novartis Pharmaceuticals Corporation $19.6211/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200435031 CMS
ABBVIE INC. $142.1010/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1204589560 CMS
Galderma Laboratories, L.P. $1.5210/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234712875 CMS
PFIZER INC. $8.0010/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230767551 CMS
ABBVIE INC. $24.6710/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204589556 CMS
ABBVIE INC. $4,550.0010/17/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1204589552 CMS
Galderma Laboratories, L.P. $3.3910/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234712873 CMS
PFIZER INC. $16.7910/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230758615 CMS
Galderma Laboratories, L.P. $5,400.0010/10/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234712871 CMS
LEO Pharma Inc. $21.8410/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252041112 CMS
PFIZER INC. $5.0510/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230573415 CMS
ABBVIE INC. $24.1710/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204589547 CMS
Galderma Laboratories, L.P. $121.4110/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234712869 CMS
Galderma Laboratories, L.P. $2.3509/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234712867 CMS
E.R. Squibb & Sons, L.L.C. $33.0109/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184538364 CMS
Galderma Laboratories, L.P. $2,250.0009/08/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234712865 CMS
LEO Pharma Inc. $14.9609/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252041110 CMS
ABBVIE INC. $24.4609/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204589543 CMS
ABBVIE INC. $10.2408/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204589539 CMS
PFIZER INC. $6.5508/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230543985 CMS
Organon LLC $15.4708/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237704784 CMS
Galderma Laboratories, L.P. $1.9208/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234712863 CMS
Galderma Laboratories, L.P. $2,250.0008/13/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234712859 CMS
Galderma Laboratories, L.P. $2,250.0008/13/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234712861 CMS
PFIZER INC. $9.8908/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230537594 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $1,760.0008/11/2025 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: NEW
06/30/2026 1251004854 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $20.9508/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251004852 CMS
PFIZER INC. $15.8208/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230598321 CMS
Galderma Laboratories, L.P. $600.0008/01/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234712857 CMS
ABBVIE INC. $14.4607/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204589535 CMS
Galderma Laboratories, L.P. $2,250.0007/28/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234712855 CMS
Galderma Laboratories, L.P. $2.9407/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234712853 CMS
Amgen Inc. $20.8307/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228363913 CMS
ABBVIE INC. $29.9907/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204589531 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $84.9907/22/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1251004846 CMS
PFIZER INC. $6.9407/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230515180 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $552.30 6
PY2021 $20.58 2
PY2022 $48,468.79 34
PY2023 $36,129.11 23
PY2024 $13,422.38 31
PY2025 $55,519.33 95

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,060.90 1
PY2025 Principal investigator $231,668.48 30
PY2024 Principal investigator $2,302.64 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

31 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,750.00 12/18/2025 Non-covered Recipient Entity
Discover Dermatology LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431464
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,836.00 11/13/2025 Non-covered Recipient Entity
Discover Dermatology LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431458
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $16,311.29 10/30/2025 Non-covered Recipient Entity
Hickory Dermatology Research Center
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235996897
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,879.37 10/29/2025 Non-covered Recipient Entity
THE SKIN SURGERY CENTER FOR CL
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223287785
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,040.00 10/23/2025 Non-covered Recipient Entity
Discover Dermatology LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431450
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $378.18 10/22/2025 Non-covered Recipient Entity
THE SKIN SURGERY CENTER FOR CL
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223287241
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,750.00 10/09/2025 Non-covered Recipient Entity
Discover Dermatology LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431444
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $157.50 09/26/2025 Non-covered Recipient Entity
THE SKIN SURGERY CENTER FOR CLINICAL RESEARCH
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223285925
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,359.40 09/26/2025 Non-covered Recipient Entity
THE SKIN SURGERY CENTER FOR CLINICAL RESEARCH
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223285973
Principal investigator 1 PFIZER INC. $68.00 09/03/2025 Non-covered Recipient Entity
Discover Dermatology LLC
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228716501
Principal investigator 1 Eli Lilly and Company $25,222.00 08/28/2025 Non-covered Recipient Entity
DISCOVER DERMATOLOGY LLC DBA HICKORY DERMATOLOGY RESEARCH CENTER
A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) No dispute reported 06/30/2026 1187883648
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $225.00 08/27/2025 Non-covered Recipient Entity
THE SKIN SURGERY CENTER FOR CLINICAL RESEARCH
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223284655
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,836.00 08/13/2025 Non-covered Recipient Entity
Discover Dermatology LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431438
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,828.00 08/12/2025 Non-covered Recipient Entity
Discover Dermatology LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431434
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,806.99 08/01/2025 Non-covered Recipient Entity
THE SKIN SURGERY CENTER FOR CLINICAL RESEARCH
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223283625
Recipient Eli Lilly and Company $3,060.90 07/17/2025 Covered Recipient Physician A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) No dispute reported 06/30/2026 1187873337
Principal investigator 1 PFIZER INC. $1,076.00 07/16/2025 Non-covered Recipient Entity
Discover Dermatology LLC
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228715327
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,797.58 07/09/2025 Non-covered Recipient Entity
THE SKIN SURGERY CENTER FOR CLINICAL RESEARCH
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223282474
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,019.11 06/06/2025 Non-covered Recipient Entity
THE SKIN SURGERY CENTER FOR CLINICAL RESEARCH
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223280916
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,661.70 05/28/2025 Non-covered Recipient Entity
THE SKIN SURGERY CENTER FOR CLINICAL RESEARCH
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223280482
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $9,000.00 05/08/2025 Non-covered Recipient Entity
Discover Dermatology LLC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246431432
Principal investigator 1 PFIZER INC. $9,250.00 05/02/2025 Non-covered Recipient Entity
Discover Dermatology LLC
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228715325
Principal investigator 1 PFIZER INC. $1,750.00 05/02/2025 Non-covered Recipient Entity
Discover Dermatology LLC
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228715579
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,026.32 04/18/2025 Non-covered Recipient Entity
THE SKIN SURGERY CENTER FOR CLINICAL RESEARCH
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223278510
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $264.00 04/18/2025 Non-covered Recipient Entity
THE SKIN SURGERY CENTER FOR CLINICAL RESEARCH
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223278518
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,761.39 03/05/2025 Non-covered Recipient Entity
THE SKIN SURGERY CENTER FOR CLINICAL RESEARCH
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223276027
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $22,142.20 02/14/2025 Non-covered Recipient Entity
THE SKIN SURGERY CENTER FOR CLINICAL RESEARCH
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223275331
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $75.00 02/03/2025 Non-covered Recipient Entity
THE SKIN SURGERY CENTER FOR CLINICAL RESEARCH
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223274683
Principal investigator 1 Amgen Inc. $59,697.60 01/29/2025 Non-covered Recipient Entity
OBJECTIVE GI INC
A comparative cohort study to assess differences in sleep efficiency between patients with atopic d No dispute reported 06/30/2026 1246645787
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $528.00 01/24/2025 Non-covered Recipient Entity
THE SKIN SURGERY CENTER FOR CLINICAL RESEARCH
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223274473
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,171.85 01/03/2025 Non-covered Recipient Entity
THE SKIN SURGERY CENTER FOR CLINICAL RESEARCH
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223273547